Current approaches to systemic treatment of BRCA-associated triple-negative breast cancer
| Autor: | D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, L. F. Shaikhelislamova, L. P. Gigolaeva, V. F. Semiglazov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Успехи молекулярной онкологии, Vol 10, Iss 3, Pp 8-14 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2313-805X 2413-3787 |
| DOI: | 10.17650/2313-805X-2023-10-3-8-14 |
| Popis: | BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for a long time in the context of the treatment of metastatic BRCA-associated TNBC. Neoadjuvant regimens based on the use of anthracyclines and taxanes are the standard of drug therapy for primary BRCA-associated breast cancer. At present, there are few data regarding the addition of platinum drugs to anthracycline-taxane neoadjuvant chemotherapy in the treatment of primary BRCA-associated TNBC. This review details the various treatment options for both primary and metastatic BRCA-associated TNBC. It has been shown that the development of new strategies for the neoadjuvant chemotherapy of patients with primary BRCA-associated TNBC is an urgent clinical need to reduce the risks of recurrence and progression. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|